ReviewTrends in pharmacological sciences2023
Celiac disease: mechanisms and emerging therapeutics.
Review in Trends in pharmacological sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 37 citations in OpenAlex.
- Molecular histomorphometry and the emerging role of transcriptomics in celiac disease diagnosis and therapeutic trials.Annals of medicine · 2026Review
- Targeted enzymatic therapy for coeliac disease.EMBO molecular medicine · 2026Article
- Review
- Human Transglutaminases: Updated Insights into Activation Mechanisms, Allosteric Regulation and Disease.International journal of molecular sciences · 2026Review
- Microbial transglutaminase in food biotechnology: from biochemical mechanisms to industrial applications.Applied microbiology and biotechnology · 2026Review
- Maternal Folic Acid, B12, and Zinc Serum Levels and Risk of Orofacial Cleft in Offspring in Tabriz.Medical journal of the Islamic Republic of Iran · 2026Article
- Gut mucosal immune responses - Implications for celiac disease and food allergy.Seminars in immunology · 2025Review
- Potential Transfer of Toxic Gluten from Biodegradable Tableware to Gluten-Free Foods: Implications for Individuals with Gluten-Related Disorders.Journal of agricultural and food chemistry · 2025Article
- A dendritic cell population responsible for transglutaminase 2-mediated gluten antigen presentation in celiac disease.JCI insight · 2025Article
- Gluten Proteins: Beneficial Factors and Toxic Triggers in Human Health.Foods (Basel, Switzerland) · 2025Review
- Lactiplantibacillus plantarum Moderating Effect on Autoimmune Celiac Disease Triggers.Probiotics and antimicrobial proteins · 2025Review
- Uncovering Hidden Gluten Exposure in Celiac Patients: A Case Study in Family-Based Management and the Role of Point-of-Care Urine Testing and Psychological Assessment.International journal of molecular sciences · 2025Article
- Article
- Mucus and mucin: changes in the mucus barrier in disease states.Tissue barriers · 2025Review
- Editorial: Gluten-related disorders: pathogenesis, diagnosis, and treatment.Frontiers in nutrition · 2025Article
- Impact of ESPGHAN no-biopsy strategy on the outcome of celiac disease treatment in children.Frontiers in pediatrics · 2025Article
- Rapid Gluten Allergen Detection Using an Integrated Photoimaging Assay and Ionic Liquid Extraction Sensor.ACS omega · 2024Article
- Coeliac Disease in Children-A Clinical Review Including Novel Treatment Agents.Medicina (Kaunas, Lithuania) · 2024Review
- Structural and mechanistic analysis of CaProceedings of the National Academy of Sciences of the United States of America · 2024Article
- Transcriptomic analysis of celiac disease treatment with transglutaminase 2 inhibitor.Nature immunology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Celiac disease (CeD) is a widespread, gluten-induced, autoimmune disorder that lacks any medicinal therapy. Towards the goal of developing non-dietary treatments for CeD, research has focused on elucidating its molecular and cellular etiology. A model of pathogenesis has emerged centered on interactions between three molecular families: specific class II MHC proteins on antigen-presenting cells (APCs), deamidated gluten-derived peptides, and T cell receptors (TCRs) on inflammatory CD4
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.